NASDAQ · KOD
Healthcare · Biotechnology
$32.99
Down-$0.15 (-0.45%)
Updated Sep 16, 2026, 12:50 PM
SID Score
4.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
KOD closed at $32.99 after 20 trading sessions, down 18.84% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $32.71 | $33.29 | $32.375 | $32.99 | 819.59K |
| Sep 14, 2026 | $33.21 | $33.89 | $32.96 | $33.14 | 547.79K |
| Sep 11, 2026 | $33.10 | $34.07 | $32.31 | $32.89 | 682.57K |
| Sep 10, 2026 | $33.29 | $33.41 | $32.61 | $32.87 | 668.38K |
| Sep 9, 2026 | $35.00 | $35.925 | $33.73 | $33.78 | 643.55K |
| Sep 8, 2026 | $34.71 | $35.27 | $33.92 | $35.07 | 673.16K |
| Sep 4, 2026 | $35.98 | $36.62 | $35.18 | $35.36 | 675.92K |
| Sep 3, 2026 | $37.60 | $37.815 | $36.20 | $36.36 | 460.19K |
| Sep 2, 2026 | $37.44 | $39.54 | $36.61 | $37.50 | 507.49K |
| Sep 1, 2026 | $37.01 | $38.105 | $36.70 | $37.06 | 391.61K |
| Aug 31, 2026 | $37.28 | $37.76 | $35.50 | $37.35 | 1.15M |
| Aug 28, 2026 | $38.73 | $39.62 | $37.40 | $37.72 | 469.18K |
| Aug 27, 2026 | $39.37 | $40.11 | $38.6496 | $39.12 | 475.42K |
| Aug 26, 2026 | $39.94 | $40.0275 | $38.40 | $39.33 | 296.81K |
| Aug 25, 2026 | $37.99 | $39.68 | $37.70 | $39.46 | 571.32K |
| Aug 24, 2026 | $38.33 | $38.90 | $36.46 | $37.22 | 717.5K |
| Aug 21, 2026 | $40.39 | $40.90 | $37.99 | $38.33 | 509.12K |
| Aug 20, 2026 | $39.50 | $40.515 | $38.69 | $39.84 | 486.65K |
| Aug 19, 2026 | $41.72 | $41.72 | $39.30 | $40.07 | 595.82K |
| Aug 18, 2026 | $40.06 | $40.94 | $39.06 | $40.65 | 623.78K |
The latest Smart Investors Daily articles mentioning KOD.
KOD research
Company profile and research snapshot.
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 17, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 3, 2026 | JP Morgan | Overweight | — |
| May 11, 2026 | Chardan Capital | Buy | — |
| Mar 27, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 27, 2026 | UBS | Buy | — |
Generated Sep 16, 2026, 11:14 AM
Kodiak Sciences Inc. (KOD) is trading down $0.15 (0.45%) in a modest decline that reflects broader market positioning around the biotech sector's near-term catalysts. The stock appears caught in the typical volatility pattern of small-cap biotechs as investors reassess binary event risks on the company's clinical and regulatory calendar.
Bottom line: Kodiak Sciences' modest 0.45% decline appears driven by typical small-cap biotech volatility rather than company-specific negative news, with upcoming binary catalysts positioning the stock as a potential event-driven trade. Investors should monitor the timeline and nature of these catalysts closely, as positive readouts could drive material upside while negative results pose significant downside risk.
Yahoo · Sep 13, 2026
Kodiak Sciences, Capricor Therapeutics and Invivyd each face pivotal clinical trial or FDA decisions before the end of 2026 that could significantly move their stock prices.
Yahoo · Sep 3, 2026
On August 13, Kodiak Sciences Inc. (NASDAQ:KOD) reported second-quarter financial results for the period ended June 30, alongside an update on its three late-stage eye disease programs. The clinical-stage biotech told investors it now sits within months of three separate Phase 3 readouts, a stretch CEO Victor Perlroth called the payoff of years of disciplined […]
Benzinga · Aug 17, 2026
HC Wainwright & Co. analyst Matthew Caufield reiterates Kodiak Sciences (NASDAQ:KOD) with a Buy and maintains $58 price target.
Benzinga · Aug 13, 2026
Kodiak Sciences (NASDAQ:KOD) reported quarterly losses of $(1.05) per share which missed the analyst consensus estimate of $(0.95) by 10.53 percent. This is a 1.94 percent decrease over losses of $(1.03) per share from
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning KOD.
